Benefit Assessment of Adding Irinotecan to Capecitabine-Based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
Results of the first phase III study to evaluate the use of the UGT1A1 genotype for guiding the irinotecan dose in this setting